13F-HR filed by NEA Management Company, LLC
NEA Management Company, LLC filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-14, with 29 holding rows worth $1,822,265,067.
- Accession
- 0000897069-25-001705
- Filer
- CIK 1512848
- Filed
- 2025-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2025
A holdings report, 29 entries on the cover page, a total value of $1,822,265,067 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,822,265,067 with VALUE read as dollars as filed, 13F file number 028-14302. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| RHYTHM PHARMACEUTICALS INC | 76243J105 | COM | 2,909,956 | $293,876,456 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 3,045,262 | $250,016,010 | dollars as filed | |
| VERONA PHARMA PLC | 925050106 | SPONSORED ADS | 2,252,994 | $240,416,990 | dollars as filed | |
| COURSERA INC COM | 22266M104 | Stock | 12,867,769 | $150,681,575 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 13,222,228 | $120,983,386 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 2,144,261 | $105,926,493 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 24,471,264 | $87,362,412 | dollars as filed | |
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 1,058,570 | $68,605,922 | dollars as filed | |
| MBX BIOSCIENCES INC COM | 55287L101 | Stock | 3,614,486 | $63,253,505 | dollars as filed | |
| ZENAS BIOPHARMA INC COM | 98937L105 | Stock | 2,733,719 | $60,688,562 | dollars as filed | |
| MONTE ROSA THERAPEUTICS INC | 61225M102 | COM | 7,692,298 | $56,999,928 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 1,090,793 | $52,238,077 | dollars as filed | |
| ORIC PHARMACEUTICALS INC | 68622P109 | COM | 4,118,621 | $49,423,452 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 18,093,034 | $47,584,679 | dollars as filed | |
| AURINIA PHARMACEUTICALS INC COM | 05156V102 | Stock | 3,969,834 | $43,866,666 | dollars as filed | |
| PHATHOM PHARMACEUTICALS INC | 71722W107 | COMMON STOCK | 1,960,169 | $23,071,189 | dollars as filed | |
| NEUEHEALTH INC | 10920V404 | COM NEW | 2,726,917 | $18,188,536 | dollars as filed | |
| BLACK DIAMOND THERAPEUTICS I | 09203E105 | COM | 4,448,757 | $16,860,789 | dollars as filed | |
| CVRX INC | 126638105 | COMMON STOCK | 2,026,083 | $16,350,490 | dollars as filed | |
| CHAMPIONS ONCOLOGY INC | 15870P307 | COM NEW | 1,713,720 | $11,096,337 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 1,462,586 | $8,322,823 | dollars as filed | |
| OMADA HEALTH INC | 68170A108 | COM | 364,115 | $8,050,583 | dollars as filed | |
| X4 Pharmaceuticals, Inc. | 98420X103 | COM | 2,233,743 | $7,639,401 | dollars as filed | |
| NKARTA INC | 65487U108 | COMMON STOCK | 3,568,781 | $7,387,377 | dollars as filed | |
| Senti Biosciences, Inc. | 81726A209 | COM NEW | 3,775,615 | $5,323,617 | dollars as filed | |
| SYNLOGIC INC | 87166L209 | COM | 2,922,772 | $4,875,184 | dollars as filed | |
| MARKER THERAPEUTICS INC | 57055L206 | COM NEW | 1,625,678 | $1,451,080 | dollars as filed | |
| ONKURE THERAPEUTICS INC | 68277Q105 | COM CL A | 478,548 | $1,316,007 | dollars as filed | |
| IMAGENEBIO INC | 45175G207 | CMN | 50,005 | $407,541 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000897069-25-001705 | this filing | 2025-11-14 | acceptance time not in the bulk data set |